ABVC Biopharma FY26 Q2 net loss narrows 65% to $810,481

• ABVC Biopharma posted a Q2 net loss of $810,481, narrowing 65% from the year-earlier quarter.
• Operating loss tightened to $779,526 as operating expenses fell 66% to $779,526, on lower stock-based compensation.
• Interest expense eased 62% to $41,640, helping offset other expense rising to $30,955 from $14,223.
• For the first half, net loss narrowed 24% to $2.5 million; operating expenses declined 21% to $2.35 million.
• Working capital deficit widened to $5.28 million; BioKey Cayman distribution was postponed, while Vitargus Phase II remains on hold after SAEs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ABVC Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-088348), on August 12, 2026, and is solely responsible for the information contained therein.